Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma
- PMID: 20001888
- DOI: 10.1615/critrevimmunol.v29.i5.30
Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma
Abstract
Therapeutic vaccines have been developed to induce immune responses capable of eradicating lymphoma and myeloma tumors. Most of these vaccines target the immunoglobulin idiotype (Id) as a tumor-specific antigen. Phase I/II clinical trials of Id vaccination in lymphoma demonstrated that some lymphoma patients could mount immune responses that were correlated with a favorable clinical outcome. These encouraging results initiated phase III trials of Id vaccination in lymphoma, the results of which have been recently released. Disappointingly, only one of three phase III studies achieved the primary end point of progression-free survival. Detailed analysis of these results is awaited to help identify factors that determine clinical efficacy of Id vaccination as reflected in the three trials. Unlike lymphoma, studies of Id vaccination in multiple myeloma have yielded far less evidence of clinical benefit. Although Id vaccines induce immune responses in myeloma patients, their efficacy is insufficient to provide a clear clinical benefit. Strategies to improve lymphoma and myeloma vaccines are currently tested with an emphasis on optimization of antigen delivery and presentation and modulation of the immune system toward enhancement of T-cell function. Despite many hurdles yet to overcome, it is hoped that newly developed strategies that augment both immune and clinical responses will allow effective vaccination resulting in tumor eradication.
Similar articles
-
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.Haematologica. 2002 Sep;87(9):989-1001. Haematologica. 2002. PMID: 12217812 Review.
-
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.Cancer Res. 2002 Oct 15;62(20):5845-52. Cancer Res. 2002. PMID: 12384547 Clinical Trial.
-
Vaccines for lymphomas: idiotype vaccines and beyond.Blood Rev. 2009 May;23(3):137-42. doi: 10.1016/j.blre.2008.09.001. Epub 2008 Oct 31. Blood Rev. 2009. PMID: 18951668 Review.
-
B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.J Immunother. 2005 Sep-Oct;28(5):461-6. doi: 10.1097/01.cji.0000171312.16171.77. J Immunother. 2005. PMID: 16113602
-
Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48. J Immunother. 2011. PMID: 21150718 Clinical Trial.
Cited by
-
Immunotherapy for B-cell lymphoma: current status and prospective advances.Front Immunol. 2012 Jan 24;3:3. doi: 10.3389/fimmu.2012.00003. eCollection 2012. Front Immunol. 2012. PMID: 22566889 Free PMC article.
-
Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.Clin Exp Immunol. 2012 Dec;170(3):291-9. doi: 10.1111/j.1365-2249.2012.04658.x. Clin Exp Immunol. 2012. PMID: 23121670 Free PMC article.
-
Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Clin Cancer Res. 2012 Mar 1;18(5):1426-34. doi: 10.1158/1078-0432.CCR-11-1221. Epub 2012 Jan 12. Clin Cancer Res. 2012. PMID: 22241792 Free PMC article. Clinical Trial.
-
Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.PLoS One. 2012;7(9):e44870. doi: 10.1371/journal.pone.0044870. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028651 Free PMC article.
-
Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance.Oncol Lett. 2017 Sep;14(3):2657-2662. doi: 10.3892/ol.2017.6528. Epub 2017 Jul 7. Oncol Lett. 2017. PMID: 28928810 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical